The FDA has approved the Novartis drug Afinitor(everolimus) for the treatment of advanced pancreatic neuroendocrine tumors. 

Afinitor underwent rigorous clinical trials to determine the safety and effectiveness of the drug in this specific cancer type.  It was previously approved to treat other cancer types, but needed to prove efficacy in patients with pancreatic neuroendocrine tumors.  Afinitor is designed to attack specific proteins that are necessary for the growth of cancer cells.